AP-2α Antibody [H2P15] Datasheet

Biological Description

Specificity	AP-2α Antibody [H2P15] detects endogenous levels of total AP-2α protein.
Background	AP‑2α, encoded by TFAP2A, is a sequence‑specific transcription factor of the AP‑2 family that binds GC‑ and AT‑rich enhancer elements and regulates genes involved in embryonic ectodermal development, neural crest formation, cell cycle control, and apoptosis. The protein contains an N‑terminal transactivation region and a C‑terminal basic helix–span–helix domain with a dimerization motif, and homodimerization together with integrity of the basic region is required for high‑affinity DNA binding and transcriptional regulation of target promoters and enhancers. AP‑2α is expressed in early ectoderm, neural crest–derived structures, craniofacial primordia, limb buds, kidney, and other developing organs, where it activates or represses genes that control proliferation and terminal differentiation, and TFAP2A mutations that impair DNA binding cause branchio‑oculo‑facial syndrome with defects in first and second branchial arch derivatives. The factor functions downstream of signal‑transduction pathways that converge on its regulatory regions, as protein kinase C– and cAMP‑dependent signaling modulate AP‑2‑mediated transactivation, and AP‑2 family members integrate these inputs to regulate genes such as ERBB2/c‑erbB‑2 and other growth‑ and survival‑related loci in a context‑dependent manner. AP‑2α cooperates with or counteracts other transcriptional regulators, including AP‑2β and AP‑2γ, to generate tissue‑specific combinations of AP‑2/DNA complexes, and these combinations influence whether a given target gene is activated or repressed in particular embryonic and tumor cell types. In adult skin, AP‑2α is the predominant AP‑2 family member in epidermis and, together with AP‑2β, regulates keratinocyte differentiation and epidermal homeostasis, with loss of AP‑2α leading to impaired terminal differentiation, abnormal hair morphogenesis, and subsequent inflammatory changes. AP‑2α also shows expression in the nephron, where it participates in the regulation of distal nephron segment differentiation in conjunction with AP‑2β, indicating a broader role in epithelial segment identity and function. Across cancers, TFAP2A expression and activity correlate with altered regulation of genes controlling proliferation, apoptosis, adhesion, and migration, and AP‑2α can associate with either oncogenic or tumor‑suppressive patterns of gene expression depending on tumor type and interaction partners, with effects reported on pathways such as HIF‑1α/VEGF and receptor tyrosine kinase networks.

Specificity

AP-2α Antibody [H2P15] detects endogenous levels of total AP-2α protein.

Background

AP‑2α, encoded by TFAP2A, is a sequence‑specific transcription factor of the AP‑2 family that binds GC‑ and AT‑rich enhancer elements and regulates genes involved in embryonic ectodermal development, neural crest formation, cell cycle control, and apoptosis. The protein contains an N‑terminal transactivation region and a C‑terminal basic helix–span–helix domain with a dimerization motif, and homodimerization together with integrity of the basic region is required for high‑affinity DNA binding and transcriptional regulation of target promoters and enhancers. AP‑2α is expressed in early ectoderm, neural crest–derived structures, craniofacial primordia, limb buds, kidney, and other developing organs, where it activates or represses genes that control proliferation and terminal differentiation, and TFAP2A mutations that impair DNA binding cause branchio‑oculo‑facial syndrome with defects in first and second branchial arch derivatives. The factor functions downstream of signal‑transduction pathways that converge on its regulatory regions, as protein kinase C– and cAMP‑dependent signaling modulate AP‑2‑mediated transactivation, and AP‑2 family members integrate these inputs to regulate genes such as ERBB2/c‑erbB‑2 and other growth‑ and survival‑related loci in a context‑dependent manner. AP‑2α cooperates with or counteracts other transcriptional regulators, including AP‑2β and AP‑2γ, to generate tissue‑specific combinations of AP‑2/DNA complexes, and these combinations influence whether a given target gene is activated or repressed in particular embryonic and tumor cell types. In adult skin, AP‑2α is the predominant AP‑2 family member in epidermis and, together with AP‑2β, regulates keratinocyte differentiation and epidermal homeostasis, with loss of AP‑2α leading to impaired terminal differentiation, abnormal hair morphogenesis, and subsequent inflammatory changes. AP‑2α also shows expression in the nephron, where it participates in the regulation of distal nephron segment differentiation in conjunction with AP‑2β, indicating a broader role in epithelial segment identity and function. Across cancers, TFAP2A expression and activity correlate with altered regulation of genes controlling proliferation, apoptosis, adhesion, and migration, and AP‑2α can associate with either oncogenic or tumor‑suppressive patterns of gene expression depending on tumor type and interaction partners, with effects reported on pathways such as HIF‑1α/VEGF and receptor tyrosine kinase networks.

Usage Information

Application

WB, IP, IHC, IF, FCM

Dilution

WB	IP	IHC	IF	FCM
1:1000-1:10000	1:20	1:100-1:250	1:50	1:20

Reactivity

Mouse, Rat, Human

Source

Rabbit Monoclonal Antibody

MW

48 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/16420676/
https://pubmed.ncbi.nlm.nih.gov/30824562/

AP-2α Antibody [H2P15]

Biological Description

Usage Information

References

Application Data